Adding daratumumab to bortezomib-containing therapy improves outcomes for people with newly-diagnosed immunoglobulin light-chain (AL) amyloidosis, a new study has shown. The CD38-targeted therapy increased haematologic complete response rates and survival free from major organ deterioration or haematologic progression in the international phase 3 ANDROMEDA trial, which included Australian centres. The study compared haematologic responses in ...
Daratumumab shows promise as an addition to AL amyloidosis therapy
By Natasha Doyle
5 Jul 2021